Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 4Prednisone 3Doxorubicin 3prednylidene 2deltacortene 2Vorinostat 2Vincristine 2Etoposide 2Brentuximab Vedotin 2pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1MLN 8237 1Lenalidomide 1Ki-1 Antigen 1Bortezomib 1Automobiles 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Enteropathy-Associated T-Cell Lymphoma × Ki-1 Antigen × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡